RESULTS	In secondary subgroup analyses , AD patients who had genotypes that encoded for full expression of the butyrylcholinesterase enzyme ( BuChE wt/wt ; n = 226/340 ) , who were < 75 years of age ( n = 362/994 ) or who had symptoms suggestive of concomitant Lewy body disease ( n = 49/994 ) showed significantly greater benefits from rivastigmine treatment .\